In Brief: Abbott Laboratories/Home Access
This article was originally published in The Gray Sheet
Executive SummaryAbbott Laboratories/Home Access: Firms ink exclusive agreement to collaborate on development and marketing of home diagnostic tests employing Home Access' telemedicine test reporting and patient counseling service. Under the terms of the deal, Abbott will market tests to be developed by Home Access, which is responsible for gaining FDA approval and for providing related test result counseling services. Financial terms were not disclosed. Hoffman Estates, Illinois-based Home Access says that it is conducting research in the areas of genetics, cancer, drug testing, reproductive health and nutrition. The firm is currently the only company marketing FDA-approved at-home diagnostic tests with counseling services (telemedicine) -- the Home Access and Home Access Express HIV test systems. The firm notes that the home diagnostic tests under development likely will function along the same lines as the Home Access HIV test systems, which allow people to obtain the test sample at home and anonymously obtain the results by phone...
You may also be interested in...
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.